Drug Profile

SYNB 8802

Alternative Names: SYNB-8802; SYNB-8802v1

Latest Information Update: 19 Feb 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ginkgo Bioworks; Synlogic
Developer Synlogic
Class Bacteria; Gene therapies; Probiotics
Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators; Oxalate inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Phase I Hyperoxaluria

Most Recent Events

19 Feb 2024 Development for phase-I in Hyperoxaluria is still ongoing in USA (Synlogic pipeline, February 2024)
28 Dec 2023 No recent reports of development identified for phase-I development in Hyperoxaluria in USA (PO)
15 Dec 2022 Adverse events and efficacy data from a phase-I trial in Hyperoxaluria released by Synlogic

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com